Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04139993 · ClinicalTrials.gov registry record · Phase 1
RBX7455 Before Surgery for the Treatment of Operable Breast Cancer
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04139993: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT04139993 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04139993, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This clinical trial studies the side effects and possible benefits of RBX7455 given before surgery in treating patients with breast cancer that can be removed by surgery (operable). RBX7455 contains live intestinal microbes (active drug), which are obtained from healthy human stool and may restore the normal balance of microorganisms in the intestines through the transplant of live and beneficial microorganisms.
Interventions
- DRUG Microbiota-based Formulation RBX7455
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-08-31 |
| Est. Completion | 2023-01-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04139993
The ClinicalTrials.gov registry entry for NCT04139993 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Microbiota-based Formulation RBX7455 is the first listed.
NCT04139993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04139993 about?
NCT04139993 is a clinical study titled "RBX7455 Before Surgery for the Treatment of Operable Breast Cancer". This clinical trial studies the side effects and possible benefits of RBX7455 given before surgery in treating patients with breast cancer that can be removed by surgery (operable). RBX7455 contains live intestinal microbes (active drug), which are obtained from healthy human stool and may restore t...
What is the current status of trial NCT04139993?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2020-08-31. Estimated completion is 2023-01-11.
What interventions are being tested in trial NCT04139993?
The interventions under investigation include: Microbiota-based Formulation RBX7455 (DRUG).
Who is sponsoring clinical trial NCT04139993?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.